Is UNITED THERAPEUTICS Corp (UTHR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 13.9% / 30% | 1.7% / 30% | 6.03% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 13.9% / 33% | 1.7% / 33% | 6.03% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 37.1% / 33% | 4.4% / 33% | 6.03% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 13.9% / 33% | 1.7% / 33% | 6.03% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 37.1% / 33% | 4.4% / 50% | 6.03% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 87.9% | |
| Operating Margin | 45.0% | |
| Net Margin | 41.9% | |
| Return on Equity (ROE) | 19.7% | |
| Return on Assets (ROA) | 12.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $1.6B |
| Free Cash Flow | $1.0B |
| Debt-to-Equity | 0.5 |
| Current Ratio | 6.6 |
| Total Assets | $7.9B |
Price & Trading
| Last Close | $532.53 |
| 50-Day MA | $495.92 |
| 200-Day MA | $421.24 |
| Avg Volume | 425K |
| Beta | 0.9 |
|
52-Week Range
$266.98
| |
About UNITED THERAPEUTICS Corp (UTHR)
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is UNITED THERAPEUTICS Corp (UTHR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), UNITED THERAPEUTICS Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is UNITED THERAPEUTICS Corp's debt ratio?
UNITED THERAPEUTICS Corp's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are UNITED THERAPEUTICS Corp's key financial metrics?
UNITED THERAPEUTICS Corp has a market capitalization of $22.9B, trailing P/E ratio of 18.8, and revenue of $3.2B. The company maintains a gross margin of 87.9% and a net margin of 41.9%. Return on equity stands at 19.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.